Anti-TLR4/ ARMD10/ CD284 monoclonal antibody
Anti-TLR4/ ARMD10/ CD284 antibody for FACS & in-vivo assay
Go to TLR4/TLR4 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T81443-Ab-1/ GM-Tg-hg-T81443-Ab-2 | Anti-Human TLR4 monoclonal antibody | Human |
GM-Tg-rg-T81443-Ab-1/ GM-Tg-rg-T81443-Ab-2 | Anti-Rat TLR4 monoclonal antibody | Rat |
GM-Tg-mg-T81443-Ab-1/ GM-Tg-mg-T81443-Ab-2 | Anti-Mouse TLR4 monoclonal antibody | Mouse |
GM-Tg-cynog-T81443-Ab-1/ GM-Tg-cynog-T81443-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TLR4 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T81443-Ab-1/ GM-Tg-felg-T81443-Ab-2 | Anti-Feline TLR4 monoclonal antibody | Feline |
GM-Tg-cang-T81443-Ab-1/ GM-Tg-cang-T81443-Ab-2 | Anti-Canine TLR4 monoclonal antibody | Canine |
GM-Tg-bovg-T81443-Ab-1/ GM-Tg-bovg-T81443-Ab-2 | Anti-Bovine TLR4 monoclonal antibody | Bovine |
GM-Tg-equg-T81443-Ab-1/ GM-Tg-equg-T81443-Ab-2 | Anti-Equine TLR4 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T81443-Ab-1/ GM-Tg-hg-T81443-Ab-2; GM-Tg-rg-T81443-Ab-1/ GM-Tg-rg-T81443-Ab-2; GM-Tg-mg-T81443-Ab-1/ GM-Tg-mg-T81443-Ab-2; GM-Tg-cynog-T81443-Ab-1/ GM-Tg-cynog-T81443-Ab-2; GM-Tg-felg-T81443-Ab-1/ GM-Tg-felg-T81443-Ab-2; GM-Tg-cang-T81443-Ab-1/ GM-Tg-cang-T81443-Ab-2; GM-Tg-bovg-T81443-Ab-1/ GM-Tg-bovg-T81443-Ab-2; GM-Tg-equg-T81443-Ab-1/ GM-Tg-equg-T81443-Ab-2 |
Products Name | Anti-TLR4 monoclonal antibody |
Format | mab |
Target Name | TLR4 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-TLR4 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species TLR4/ ARMD10/ CD284 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLV000034 | human TLR4 Lentivirus plasmid |
ORF Viral Vector | vGMLV000034 | human TLR4 Lentivirus particle |
ORF Viral Vector | pGMAD000527 | house mouse Tlr4 Adenovirus plasmid |
ORF Viral Vector | pGMAAV000078 | mouse Tlr4 AAV plasmid |
ORF Viral Vector | vGMAD000527 | house mouse Tlr4 Adenovirus particle |
ORF Viral Vector | vGMAAV000078 | mouse Tlr4 AAV particle |
Target information
Target ID | GM-T81443 |
Target Name | TLR4 |
Gene ID | 7099,21898,29260,574360,403417,493698,281536,100066890 |
Gene Symbol and Synonyms | ARMD10,CD284,hToll,Lps,Ly87,Ran/M1,Rasl2-8,TLR-4,TLR4,TOLL |
Uniprot Accession | O00206,Q9QX05,P58727,Q9GL65,Q9MYW3 |
Uniprot Entry Name | TLR4_HUMAN,TLR4_RAT,TLR4_FELCA,TLR4_BOVIN,TLR4_HORSE |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target |
Disease | Cancer |
Gene Ensembl | ENSG00000136869 |
Target Classification | Checkpoint-Immuno Oncology, Tumor-associated antigen (TAA) |
The target: TLR4, gene name: TLR4, also named as ARMD10, CD284, TLR-4, TOLL. The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. In silico studies have found a particularly strong binding of surface TLR4 with the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease-2019 (COVID-19). This receptor has also been implicated in signal transduction events induced by lipopolysaccharide (LPS) found in most gram-negative bacteria. Mutations in this gene have been associated with differences in LPS responsiveness, and with susceptibility to age-related macular degeneration. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.